Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma |
| |
| Affiliation: | 1. Department of Laboratory Medicine, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan;2. Department of Dermatology, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan;1. Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;2. Department of Infectious Diseases, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;3. Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;4. Clinical Laboratories, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;5. Department of Neurology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;1. AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan;2. Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University, 1-1, Seriryo-tyo, Aoba-ku, Sendai, Miyagi, Japan;3. Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5, Nakauchi-machi, Misasagi, Yamashina-ku, Kyoto-shi, Kyoto, Japan;4. Department of Pharmacy, Shizuoka Cancer Center Hospital, Shizuoka, 1007, Shimonagakubo, Nagaizumi-cho, Sundo-gun, Shizuoka, Japan;5. Division of Infectious Diseases, Shizuoka Cancer Center Hospital, 1007, Shimonagakubo, Nagaizumi-cho, Sundo-gun, Shizuoka, Japan;1. Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, School of Medicine, University of Crete, 71110 Voutes, Heraklion, Crete, Greece;2. Department of Clinical Microbiology, University Hospital of Heraklion, School of Medicine, University of Crete, 71110 Voutes, Heraklion, Crete, Greece;3. National Reference Laboratory for Staphylococci, Department of Microbiology, School of Medicine, University of Patras, Patras, Greece;1. Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Nishi 2-11, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan;2. Diagnostic Center for Animal Health and Food Safety, Obihiro University of Agriculture and Veterinary Medicine, Nishi 2-11, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan;3. Division of Clinical Research, Medical Mycology Research Center, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba, 260-8673, Japan;4. Department of Medical Technologist, Obihiro-Kosei General Hospital, West 14 South 10-1, Obihiro, Hokkaido, 080-0016, Japan;5. Department of Nutrition Science, University of Nagasaki, Nagasaki, Japan;6. Division of Bio-resources, Medical Mycology Research Center, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba, 260-8673, Japan;1. Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan;2. Department of General Internal Medicine, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan;3. Department of Pediatrics, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan;1. Department of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;2. Respiratory Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan;3. Department of Respiratory Medicine, Yokohama Minamikyousai Hospital, 1-21-1 Mutsuurahigashi, Kanazawa-ku, Yokohama, 236-0037, Japan |
| |
| Abstract: | We report a Japanese patient with HIV-associated Kaposi sarcoma (KS) who had many cutaneous KS lesions with extensive bilateral groin edema. As the KS was refractory to antiretroviral therapy and pegylated liposomal doxorubicin (PLD), he was administered PLD up to a cumulative dose of 940 mg/m2 in 10 years, which exceeded the recommended lifetime dose (550 mg/m2). However, the patient showed no major adverse events, including cardiotoxicity, and he eventually died of pancreatic cancer. |
| |
| Keywords: | HIV Kaposi sarcoma Pegylated liposomal doxorubicin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
